By Jim Campbell
June 12th, 2021
In an interesting decision, the FDA approved a new treatment for Alzheimer’s disease.
What made it interesting? In half the patients it showed no effect.
The disease did attack the principal cause of the disease the build up of myeline in the brain.
Biogen’s new treatment doesn’t work on everyone but it does have a target the drug appears to work on.
That’s myelin the principal target that leads to clogging the arteries in the brain for about half the patients treated.
Biogen has agreed to conduct further clinical trials to study side effects and efficacy of their new agent.